Mrázová M, Smelhausová M, Sestáková Z, Svandová E, Benes C
Centre of Epidemiology and Microbiology, NRL for mumps, measles and rubella, National Institute of Public Health, Prague, Czech Republic.
Cent Eur J Public Health. 2003 Dec;11 Suppl:S50-3.
In total, 3,010 sera from a representative population sample of the Czech Republic aged from 1 to 64 years were tested according to the requirements of the ESEN 2 project using a commercial kit Mumps IgG (II) EIA manufactured by Denka Seiken, Japan. To date, the regular programme of vaccination against mumps has covered the population of children under 15 years of age. The vaccination coverage achieved (97-100%) does not correspond to the antibody prevalence rates of 70.2 to 86.4% as found. After implementation of regular vaccination in 1987, the morbidity rates have fallen dramatically. Nevertheless, the collective immunity achieved is not sufficient to prevent epidemics of mumps.
根据ESEN 2项目的要求,使用日本Denka Seiken公司生产的腮腺炎IgG(II)酶免疫分析商业试剂盒,对来自捷克共和国1至64岁具有代表性人群样本的3010份血清进行了检测。迄今为止,常规的腮腺炎疫苗接种计划覆盖了15岁以下的儿童人群。所达到的疫苗接种覆盖率(97 - 100%)与所发现的70.2%至86.4%的抗体流行率不相符。1987年实施常规疫苗接种后,发病率大幅下降。然而,所实现的群体免疫不足以预防腮腺炎的流行。